Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis

Next Previous
Trial Profile

Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mivocabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 24 Sep 2025 Results presented in the Kyverna Therapeutics Media Release.
  • 24 Sep 2025 According to a Kyverna Therapeutics media release, updated data from this study will be presented at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, taking place in Barcelona, Spain from September 24-26, 2025, including an oral presentation from Stanford Medicine (Stanford), Department of Neurology & Neurological Sciences and a poster presentation from the University of California, San Francisco (UCSF), Weill Institute for Neurosciences.
  • 12 Aug 2025 According to a Kyverna Therapeutics media release, data of KYV-101 in MS to be showcased at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in September 2025, including an oral presentation on KYV-101 from Stanford University and a poster presentation from the University of California, San Francisco (UCSF).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top